Results 61 to 70 of about 19,724 (181)

Dermatomyositis Like Presentation of Anti‐HMGCR Immune Mediated Necrotising Myopathy

JEADV Clinical Practice, EarlyView.
ABSTRACT Extramuscular manifestations of anti‐3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) immune‐mediated necrotising myopathy (IMNM) are rare and often overlooked because they are overshadowed by predominant muscular symptoms. The types of cutaneous manifestations can be numerous.
Lionel Leblanc, Lyna Mtimet, Louis Wolff, Evelyne Berlingin, Bruno Couturier   +4 more
wiley   +1 more source

Aetiopathogenesis of Vitiligo

Dermatology Practical & Conceptual, 2023
Vitiligo is a chronic auto-immune disease characterized by skin depigmentation due to the loss of melanocytes. The better understanding of the disease mechanisms is currently undergoing a significant dynamism, opening a new era in therapeutic development.
openaire   +3 more sources

The Pathogenesis of Vitiligo

Journal of Cutaneous Medicine and Surgery, 2011
Background: Vitiligo is a commonly encountered pigmentary disorder. Numerous studies and investigations from all over the world have attempted to determine the mechanisms behind this disease; however, the pathogenesis of vitiligo remains elusive. Objective: In this comprehensive review article, we present the findings behind the five overarching ...
Marlene Dytoc, Neel Malhotra
openaire   +5 more sources

Vitiligo with special emphasis on vitiligo surgery

Archives of Medicine and Health Sciences, 2020
Vitiligo is a common form of localized depigmentation. It is an acquired hypomelanotic condition resulting from the progressive loss of melanocytes. It is characterized by milky white macules. It can be associated with tremendous psychological trauma. A number of medical treatment options exist in the armamentarium of a dermatologist treating vitiligo.
PK Ashwini, DJ Sushmitha, S Veeranna
openaire   +3 more sources

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

Med Research, EarlyView.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo   +8 more
wiley   +1 more source

Genetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci

Frontiers in Genetics, 2016
Vitiligo is an autoimmune disease with a strong genetic component, characterized by areas of depigmented skin resulting from loss of epidermal melanocytes.
Chang eShen, Jing eGao, Yu Jun Sheng, Jinfa eDou, Fusheng eZhou, Xiaodong eZheng, Randy eKo, Xianfa eTang, Caihong Hong Zhu, Xianyong Yong Yin, Liangdan Dan Sun, Yong eCui, Xue Jun Zhang   +12 more
doaj   +1 more source

Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First‐Line Programmed Cell Death Protein 1 Monotherapy

The Journal of Dermatology, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in patients with advanced malignant melanoma (MM). However, more than half of patients receiving anti‐programmed cell death protein‐1 (PD‐1) antibody monotherapy still fail to respond, with response rates varying by race and melanoma subtype.
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara   +4 more
wiley   +1 more source

Survivorship Needs and Experiences of Survivors of Head and Neck Cancer in Rural Australia: A Qualitative Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Semi‐structured interviews with 17 rural head and neck cancer survivors revealed six main themes relating to their survivorship needs and experiences: 1) financial impacts, 2) physical effects, 3) psychosocial effects, 4) clinical management, 5) information and support needs, and 6) access.
Poorva Pradhan, Helen Hughes, Ashleigh R. Sharman, Judith Lacey, Patrick Dwyer, Jacques Hill, Kimberley J. Davis, Steven Craig, Raymond Wu, Bruce Ashford, Jenny Mitchell, Jonathan R. Clark, Michael Elliott, Carsten E. Palme, Rebecca L. Venchiarutti   +14 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

New Topical and Systemic Treatments for Atopic Dermatitis

Clinical &Experimental Allergy, EarlyView.
This review summarises new topical and systemic treatments for atopic dermatitis, their relative effectiveness, and important safety data. ABSTRACT Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing–remitting course.
Sara Mirali, Aaron M. Drucker
wiley   +1 more source